- Global Pharma News & Resources

IGEA Pharma N.V.: IGEA to get SIX further approval to the 2021 annual report disclosure

IGEA Pharma N.V. / Key word(s): Annual Results/Annual Results

09-Aug-2022 / 00:30 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


IGEA to get SIX further approval to the 2021 annual report disclosure


Hoofddorp, the Netherlands, 09 August 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2021 annual report.


On request of the statutory auditors, even if the 2021 Annual Report is completed, an extra time to review and write the Independent auditor's report is needed.


In accordance with SIX’s approval, this press release sets out the relevant section of the decision:


I.  The exemption application of IGEA (Issuer) dated 25 July 2022 requesting an
extension of the deadline to publish its 2021 annual report and to file such report with
SIX Exchange Regulation AG until 31 August 2022 at the latest is granted from the
Issuers Committee of the Regulatory Board with the following reservation (lit. a and b) and under the following conditions (lit. c):


  1. Since the deadline to publish the 2021 annual report and to file such report with
    SIX Exchange Regulation AG has been extended several times, it is to be noted
    that the extension is granted for the last time until 31 August 2022.


  1. The suspension of trading of the registered shares of the Issuer remains in place
    until the 2021 annual report is published in accordance with the provisions on ad hoc publicity (Art. 53 of the Listing Rules [LR] in connection with the Directive on Ad hoc Publicity [DAH]) and filed with SIX Exchange Regulation AG.

  2.  IGEA is required to publish a notice in accordance with the provisions on ad

 hoc publicity (art. 53 LR in connection with the DAH) concerning this decision

        until Tuesday, 09 August 2022, 07.30 am CET, at the latest. The notice must




- the unaltered reproduction of the wording of para. I. of this decision,

  placed in a prominent position;

- the reasons for the application of the Issuer requesting a third

  Extension of the deadline to publish its 2021 annual report and to file

 such report with SIX Exchange Regulation AG”






About IGEA


IGEA Pharma N.V. focuses through its Joint Venture on industrial CO2 supercritical extraction of CBD and other valuable components from their vegetable matrices for health prevention, pharma, food&beverage and other selected industries, with an innovative early-stage commercial and highly diversifiable pipeline. The company aims to become a center of excellence on highly controlled vegetable matrices and their industrial extraction technology. On the other hand, Igea operates on preventative health-tech products and devices, commercializing an Alzheimer’s prevention set (which






includes ’Alz1’, an at-home lab test kit to measure non-bound copper in the blood and a natural dietary supplement branded ‘Alz1 Tab’ designed to reduce blood heavy metals content) and expects to integrate



the non-bound copper detection-based pipeline with a diabetes type II prevention set in the next future. IGEA furthermore commercializes a COVID19 rapid test for the detection of IgM and IgG SARSCoV-2 related antibodies.



IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered in Hoofddorp, the Netherlands. Find out more at









This document constitutes neither an offer to buy nor to subscribe securities and  either this document

nor any part of it should form the basis of any investment decision in IGEA. The information contained

in this press release has been carefully prepared. However, IGEA bears and assumes no liability of

whatever kind for the correctness  and completeness of the information provided herein. IGEA does not

 assume an obligation of whatever kind to update or correct information contained in this press release

whether as a result of new information, future events or for other reasons. This publication may contain

 specific forward-looking statements and assessments or intentions concerning IGEA and its business.

 Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors

 which may result in a substantial divergence between the actual results, financial situation, development,

or  performance of IGEA and those explicitly or implicitly presumed in these statements. Against the

background of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes

no responsibility to update forward looking statements or to adapt them to future events or developments,

 except as maybe required by law.



End of Inside Information
Language: English
Company: IGEA Pharma N.V.
Siriusdreef 17
2123 WT Hoofddorp
Phone: +31 23 568 9494
ISIN: NL0012768675
Listed: Regulated Unofficial Market in Frankfurt; SIX Swiss Exchange
EQS News ID: 1415687

End of Announcement EQS News Service

Editor Details

Last Updated: 08-Aug-2022